Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

(2015) K. Rajender Reddy et al.   HEPATOLOGY

Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling

(2015) Erica S. Lovelace et al.   JOURNAL OF NATURAL PRODUCTS

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

(2015) Marc Bourlière et al.   LANCET INFECTIOUS DISEASES

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

(2015) Masashi Mizokami et al.   LANCET INFECTIOUS DISEASES

Suppression of Dual Specificity Phosphatase I Expression Inhibits Hepatitis C Virus Replication

(2015) Jung Eun Choi et al.   PLoS One

Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy

(2014) Laetitia Canini et al.   ANTIVIRAL THERAPY

Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication

(2014) Steve S. Choi et al.   CLINICAL SCIENCE

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

(2014) Mark S. Sulkowski et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics

(2014) Harel Dahari et al.   LIVER INTERNATIONAL

Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial

(2014) Maria Rendina et al.   TRANSPLANT INTERNATIONAL

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice

(2013) Niu Shi et al.   GUT

Analysis of hepatitis C virus resistance to silibininin vitroandin vivopoints to a novel mechanism involving nonstructural protein 4B

(2013) Katharina Esser-Nobis et al.   HEPATOLOGY

Anti-Cancer Efficacy of Silybin Derivatives - A Structure-Activity Relationship

(2013) Chapla Agarwal et al.   PLoS One

Identification of transferrin receptor 1 as a hepatitis C virus entry factor

(2013) D. N. Martin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism

(2013) Janela McClure et al.   VIROLOGY

Legalon® SIL: The Antidote of Choice in Patients with Acute Hepatotoxicity from Amatoxin Poisoning

(2012) Ulrich Mengs et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection

(2012) Stephen J. Polyak et al.   HEPATOLOGY

Understanding silibinin’s modes of action against HCV using viral kinetic modeling

(2012) Jeremie Guedj et al.   JOURNAL OF HEPATOLOGY

Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period

(2012) Zoe Mariño et al.   JOURNAL OF HEPATOLOGY

The iron regulatory hormone hepcidin inhibits expression of iron release as well as iron uptake proteins in J774 cells

(2012) Fang Du et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Therapeutic Efficacy of Silibinin on Human Neuroblastoma Cells: Akt and NF-κB Expressions May Play an Important Role in Silibinin-Induced Response

(2012) Meysam Yousefi et al.   NEUROCHEMICAL RESEARCH

The Impact of Infection on Population Health: Results of the Ontario Burden of Infectious Diseases Study

(2012) Jeffrey C. Kwong et al.   PLoS One

Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis

(2012) Federico Salamone et al.   Translational Research

Intravenous silibinin as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin combination therapy

(2011) Karoline Rutter et al.   ANTIVIRAL THERAPY

Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase a pathway

(2011) Fang Du et al.   GLIA

Multiple effects of silymarin on the hepatitis C virus lifecycle

(2010) Jessica Wagoner et al.   HEPATOLOGY

Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor

(2010) N. Kamiya et al.   JOURNAL OF GENERAL VIROLOGY

Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy

(2010) U.P. Neumann et al.   JOURNAL OF HEPATOLOGY

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice

(2010) Eiji Ohara et al.   JOURNAL OF HEPATOLOGY

Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase

(2009) Abdelhakim Ahmed–Belkacem et al.   GASTROENTEROLOGY

Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection

(2009) Chihiro Morishima et al.   GASTROENTEROLOGY

Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon

(2009) H. Dahari et al.   JOURNAL OF VIROLOGY

Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy

(2008) Peter Ferenci et al.   GASTROENTEROLOGY